Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ampicillin + H2O
(2R,4S)-2-[(R)-[[(2R)-2-amino-2-phenylacetyl]amino](carboxy)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
carbenicillin + H2O
(2R,4S)-2-{(R)-carboxy[2-carboxy(phenyl)acetamido]methyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
nitrocefin + H2O
(2R)-2-{(R)-carboxy[2-(thiophen-2-yl)acetamido]methyl}-5-[(E)-2-(2,4-dinitrophenyl)ethenyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
penicillin G + H2O
(2R,4S)-2-[(R)-carboxy[(phenylacetyl)amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
a beta-lactam + H2O
a substituted beta-amino acid
-
-
-
-
?
a penicillin + H2O
a penicilloic acid
amoxicillin + H2O
(2R,4S)-2-[(R)-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}(carboxy)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
ampicillin + H2O
(2R,4S)-2-[(R)-[[(2R)-2-amino-2-phenylacetyl]amino](carboxy)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
azlocillin + H2O
(2R,4S)-2-[(R)-carboxy({(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl}amino)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
aztreonam + H2O
[(1S,2S)-1-[[(2Z)-2-(2-ammonio-1,3-thiazol-4-yl)-2-[[(2-carboxypropan-2-yl)oxy]imino]acetyl]amino]-1-carboxypropan-2-yl]sulfamate
benzylpenicillin + H2O
(2R,4S)-2-[(R)-carboxy(2-phenylacetamido)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
benzylpenicillin + H2O
(2R,4S)-2-[(R)-carboxy[(phenylacetyl)amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
biapenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-[(6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium-6-yl)sulfanyl]-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylate
carbapenem + H2O
[(2R)-2,3-dihydro-1H-pyrrol-2-yl]acetic acid
-
-
-
?
carbenicillin + H2O
(2R,4S)-2-{(R)-carboxy[2-carboxy(phenyl)acetamido]methyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
cefamandole + H2O
(2R)-2-[(R)-carboxy{[(2R)-2-hydroxy-2-phenylacetyl]amino}methyl]-5-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
-
?
cefazolin + H2O
(2R)-2-[(R)-carboxy[(1H-tetrazol-1-ylacetyl)amino]methyl]-5-[[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
-
?
cefepime + H2O
(2R)-2-[(R)-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino](carboxy)methyl]-5-[(1-methylpyrrolidinium-1-yl)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
cefoperazone + H2O
(2R)-2-[(R)-carboxy{[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}methyl]-5-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
-
?
cefotaxime + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino](carboxy)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
cefotiam + H2O
(2R)-2-[(R)-[2-(2-amino-1,3-thiazol-4-yl)acetamido](carboxy)methyl]-5-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
-
?
cefoxitin + H2O
(2R)-5-[(carbamoyloxy)methyl]-2-[(S)-carboxy(methoxy)[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
cefpirome + H2O
(2S)-2-[(R)-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}(carboxy)methyl]-5-[(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium-1-yl)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
-
?
cefsulodin + H2O
(2R)-5-[(4-carbamoylpyridin-1-ium-1-yl)methyl]-2-[(R)-carboxy{[(2R)-2-phenyl-2-sulfoacetyl]amino}methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
?
cefsulodine + H2O
(2R)-5-[(4-carbamoylpyridin-1-ium-1-yl)methyl]-2-[(R)-carboxy{[(2R)-2-phenyl-2-sulfoacetyl]amino}methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
?
ceftazidime + H2O
(2R)-2-[(R)-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[[(2-carboxypropan-2-yl)oxy]imino]acetyl]amino](carboxy)methyl]-5-(pyridinium-1-ylmethyl)-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
ceftazidime + H2O
(2R)-2-[(R)-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}(carboxy)methyl]-5-[(pyridin-1-ium-1-yl)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
ceftriaxone + H2O
(2R)-2-[(R)-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino](carboxy)methyl]-5-[[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)sulfanyl]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cefuroxime + H2O
(2R)-5-[(carbamoyloxy)methyl]-2-[(R)-carboxy{[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetyl]amino}methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
cephalexin + H2O
(2R)-2-[(R)-[[(2R)-2-amino-2-phenylacetyl]amino](carboxy)methyl]-5-methyl-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
-
?
cephaloridine + H2O
(2R)-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-5-(pyridinium-1-ylmethyl)-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
cephalosporin C + H2O
N6-[(R)-{(2R)-5-[(acetyloxy)methyl]-4-carboxy-3,6-dihydro-2H-1,3-thiazin-2-yl}(carboxy)methyl]-6-oxo-D-lysine
-
poor substrate
-
-
?
cephalothin + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
cephalotin + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
chromacef + H2O
(2S)-2-[(S)-carboxy(2-phenylacetamido)methyl]-5-[(E)-2-(4-nitrophenyl)ethenyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cloxacillin + H2O
(2R,4S)-2-[(R)-carboxy{[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino}methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
doripenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4-methyl-3-([(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
ertapenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-([(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl)-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
ertapenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl}sulfanyl)-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
imipenem + H2O
(5R)-3-[[2-(carbonoimidoylamino)ethyl]sulfanyl]-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4,5-dihydro-1H-pyrrole-2-carboxylic acid
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-([2-[(iminomethyl)amino]ethyl]sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-[[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl]-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
methicillin + H2O
(2R,4S)-2-[(R)-carboxy(2,6-dimethoxybenzamido)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
poor substrate
-
-
?
moxalactam + H2O
(2R)-2-{(R)-carboxy[2-carboxy(4-hydroxyphenyl)acetamido]methoxymethyl}-5-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,6-dihydro-2H-1,3-oxazine-4-carboxylic acid
nitrocefin + H2O
(2R)-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-5-[(E)-2-(2,4-dinitrophenyl)ethenyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
nitrocefin + H2O
(2R)-2-[(R)-carboxy[2-(thiophen-2-yl)acetamido]methyl]-5-[(E)-2-(2,4-dinitrophenyl)ethenyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
nitrocefin + H2O
(2R)-2-{(R)-carboxy[2-(thiophen-2-yl)acetamido]methyl}-5-[(E)-2-(2,4-dinitrophenyl)ethenyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
oxacillin + H2O
(2R,4S)-2-[(R)-carboxy[[(5-methyl-3-phenyl-1,2-oxazol-4-yl)carbonyl]amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
-
?
oxacillin + H2O
(2R,4S)-2-{(R)-carboxy[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]methyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
penicillin + H2O
?
-
-
-
?
penicillin G + H2O
(2R,4S)-2-[(R)-carboxy[(phenylacetyl)amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
penicillin N + H2O
N6-{(R)-carboxy[(2R,4S)-4-carboxy-5,5-dimethyl-1,3-thiazolidin-2-yl]methyl}-6-oxo-D-lysine
-
-
-
-
?
phenoxyethylpenicillin + H2O
(2R,4S)-2-[(R)-carboxy(3-phenoxypropanamido)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
-
?
phenoxymethylpenicillin + H2O
(2R,4S)-2-[(R)-carboxy(2-phenoxyacetamido)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
-
?
phenoxypropylpenicillin + H2O
(2R,4S)-2-[carboxy(4-phenoxybutanamido)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
-
?
piperacillin + H2O
(2R,4S)-2-[(R)-carboxy[[(2R)-2-[[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino]-2-phenylacetyl]amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
ticarcillin + H2O
(2R,4S)-2-[(R)-carboxy[[(2R)-2-carboxy-2-(thiophen-3-yl)acetyl]amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
additional information
?
-
a penicillin + H2O
a penicilloic acid
-
-
-
-
?
a penicillin + H2O
a penicilloic acid
-
-
-
?
ampicillin + H2O
(2R,4S)-2-[(R)-[[(2R)-2-amino-2-phenylacetyl]amino](carboxy)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
-
?
ampicillin + H2O
(2R,4S)-2-[(R)-[[(2R)-2-amino-2-phenylacetyl]amino](carboxy)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
ampicillin + H2O
(2R,4S)-2-[(R)-[[(2R)-2-amino-2-phenylacetyl]amino](carboxy)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
-
?
ampicillin + H2O
(2R,4S)-2-[(R)-[[(2R)-2-amino-2-phenylacetyl]amino](carboxy)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
ampicillin + H2O
(2R,4S)-2-[(R)-[[(2R)-2-amino-2-phenylacetyl]amino](carboxy)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
ampicillin + H2O
(2R,4S)-2-[(R)-[[(2R)-2-amino-2-phenylacetyl]amino](carboxy)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
ampicillin + H2O
(2R,4S)-2-[(R)-[[(2R)-2-amino-2-phenylacetyl]amino](carboxy)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
ampicillin + H2O
(2R,4S)-2-[(R)-[[(2R)-2-amino-2-phenylacetyl]amino](carboxy)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
ampicillin + H2O
(2R,4S)-2-[(R)-[[(2R)-2-amino-2-phenylacetyl]amino](carboxy)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
aztreonam + H2O
[(1S,2S)-1-[[(2Z)-2-(2-ammonio-1,3-thiazol-4-yl)-2-[[(2-carboxypropan-2-yl)oxy]imino]acetyl]amino]-1-carboxypropan-2-yl]sulfamate
-
-
-
?
aztreonam + H2O
[(1S,2S)-1-[[(2Z)-2-(2-ammonio-1,3-thiazol-4-yl)-2-[[(2-carboxypropan-2-yl)oxy]imino]acetyl]amino]-1-carboxypropan-2-yl]sulfamate
-
-
-
?
benzylpenicillin + H2O
(2R,4S)-2-[(R)-carboxy(2-phenylacetamido)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
-
?
benzylpenicillin + H2O
(2R,4S)-2-[(R)-carboxy(2-phenylacetamido)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
benzylpenicillin + H2O
(2R,4S)-2-[(R)-carboxy(2-phenylacetamido)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
benzylpenicillin + H2O
(2R,4S)-2-[(R)-carboxy(2-phenylacetamido)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
benzylpenicillin + H2O
(2R,4S)-2-[(R)-carboxy[(phenylacetyl)amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
benzylpenicillin + H2O
(2R,4S)-2-[(R)-carboxy[(phenylacetyl)amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
biapenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-[(6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium-6-yl)sulfanyl]-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylate
-
-
-
-
?
biapenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-[(6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium-6-yl)sulfanyl]-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylate
-
-
-
?
biapenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-[(6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium-6-yl)sulfanyl]-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylate
-
activity in resistant strains
-
-
?
carbenicillin + H2O
(2R,4S)-2-{(R)-carboxy[2-carboxy(phenyl)acetamido]methyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
-
?
carbenicillin + H2O
(2R,4S)-2-{(R)-carboxy[2-carboxy(phenyl)acetamido]methyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
carbenicillin + H2O
(2R,4S)-2-{(R)-carboxy[2-carboxy(phenyl)acetamido]methyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
carbenicillin + H2O
(2R,4S)-2-{(R)-carboxy[2-carboxy(phenyl)acetamido]methyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
cefepime + H2O
(2R)-2-[(R)-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino](carboxy)methyl]-5-[(1-methylpyrrolidinium-1-yl)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
-
?
cefepime + H2O
(2R)-2-[(R)-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino](carboxy)methyl]-5-[(1-methylpyrrolidinium-1-yl)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
?
cefepime + H2O
(2R)-2-[(R)-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino](carboxy)methyl]-5-[(1-methylpyrrolidinium-1-yl)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
?
cefepime + H2O
(2R)-2-[(R)-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino](carboxy)methyl]-5-[(1-methylpyrrolidinium-1-yl)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
?
cefepime + H2O
(2R)-2-[(R)-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino](carboxy)methyl]-5-[(1-methylpyrrolidinium-1-yl)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
?
cefepime + H2O
(2R)-2-[(R)-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino](carboxy)methyl]-5-[(1-methylpyrrolidinium-1-yl)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
?
cefepime + H2O
(2R)-2-[(R)-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino](carboxy)methyl]-5-[(1-methylpyrrolidinium-1-yl)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
?
cefotaxime + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino](carboxy)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
-
?
cefotaxime + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino](carboxy)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cefotaxime + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino](carboxy)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cefotaxime + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino](carboxy)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cefotaxime + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino](carboxy)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cefotaxime + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino](carboxy)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cefotaxime + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino](carboxy)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cefoxitin + H2O
(2R)-5-[(carbamoyloxy)methyl]-2-[(S)-carboxy(methoxy)[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
-
?
cefoxitin + H2O
(2R)-5-[(carbamoyloxy)methyl]-2-[(S)-carboxy(methoxy)[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cefoxitin + H2O
(2R)-5-[(carbamoyloxy)methyl]-2-[(S)-carboxy(methoxy)[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cefoxitin + H2O
(2R)-5-[(carbamoyloxy)methyl]-2-[(S)-carboxy(methoxy)[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cefoxitin + H2O
(2R)-5-[(carbamoyloxy)methyl]-2-[(S)-carboxy(methoxy)[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
ceftazidime + H2O
(2R)-2-[(R)-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[[(2-carboxypropan-2-yl)oxy]imino]acetyl]amino](carboxy)methyl]-5-(pyridinium-1-ylmethyl)-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
?
ceftazidime + H2O
(2R)-2-[(R)-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[[(2-carboxypropan-2-yl)oxy]imino]acetyl]amino](carboxy)methyl]-5-(pyridinium-1-ylmethyl)-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
?
ceftazidime + H2O
(2R)-2-[(R)-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}(carboxy)methyl]-5-[(pyridin-1-ium-1-yl)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
-
?
ceftazidime + H2O
(2R)-2-[(R)-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}(carboxy)methyl]-5-[(pyridin-1-ium-1-yl)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
?
ceftazidime + H2O
(2R)-2-[(R)-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}(carboxy)methyl]-5-[(pyridin-1-ium-1-yl)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
?
ceftazidime + H2O
(2R)-2-[(R)-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}(carboxy)methyl]-5-[(pyridin-1-ium-1-yl)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
?
ceftazidime + H2O
(2R)-2-[(R)-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}(carboxy)methyl]-5-[(pyridin-1-ium-1-yl)methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
cephalosporin antibiotic
-
-
?
cefuroxime + H2O
(2R)-5-[(carbamoyloxy)methyl]-2-[(R)-carboxy{[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetyl]amino}methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
-
?
cefuroxime + H2O
(2R)-5-[(carbamoyloxy)methyl]-2-[(R)-carboxy{[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetyl]amino}methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cefuroxime + H2O
(2R)-5-[(carbamoyloxy)methyl]-2-[(R)-carboxy{[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetyl]amino}methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cefuroxime + H2O
(2R)-5-[(carbamoyloxy)methyl]-2-[(R)-carboxy{[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetyl]amino}methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cefuroxime + H2O
(2R)-5-[(carbamoyloxy)methyl]-2-[(R)-carboxy{[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetyl]amino}methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cefuroxime + H2O
(2R)-5-[(carbamoyloxy)methyl]-2-[(R)-carboxy{[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetyl]amino}methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cefuroxime + H2O
(2R)-5-[(carbamoyloxy)methyl]-2-[(R)-carboxy{[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetyl]amino}methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cefuroxime + H2O
(2R)-5-[(carbamoyloxy)methyl]-2-[(R)-carboxy{[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetyl]amino}methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cephaloridine + H2O
(2R)-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-5-(pyridinium-1-ylmethyl)-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
-
?
cephaloridine + H2O
(2R)-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-5-(pyridinium-1-ylmethyl)-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
?
cephaloridine + H2O
(2R)-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-5-(pyridinium-1-ylmethyl)-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
?
cephaloridine + H2O
(2R)-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-5-(pyridinium-1-ylmethyl)-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
?
cephalothin + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
-
?
cephalothin + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cephalothin + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cephalothin + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cephalothin + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cephalothin + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
poor substrate
-
-
?
cephalotin + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cephalotin + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cephalotin + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cephalotin + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
cloxacillin + H2O
(2R,4S)-2-[(R)-carboxy{[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino}methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
-
?
cloxacillin + H2O
(2R,4S)-2-[(R)-carboxy{[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino}methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
cloxacillin + H2O
(2R,4S)-2-[(R)-carboxy{[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino}methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
poor substrate
-
-
?
ertapenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-([(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl)-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
ertapenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-([(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl)-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
ertapenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-([(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl)-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
imipenem + H2O
(5R)-3-[[2-(carbonoimidoylamino)ethyl]sulfanyl]-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
imipenem + H2O
(5R)-3-[[2-(carbonoimidoylamino)ethyl]sulfanyl]-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
imipenem + H2O
(5R)-3-[[2-(carbonoimidoylamino)ethyl]sulfanyl]-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
-
?
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
-
?
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
activity in resistant strains
-
-
?
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
the enzyme shows carbapenemase activity, e.g. against the carbapenem antibiotics meropenem and imipenem used in treatment of Pseudomonas aeruginosa infection, and contributes to resistance to anti-pseudomonal agents, overview
-
-
?
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
beta-lactam antibiotic
-
-
?
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
high activity of IMP-10
-
-
?
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-[[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl]-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-[[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl]-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-[[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl]-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-[[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl]-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
-
?
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
-
?
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
activity in resistant strains
-
-
?
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
the enzyme shows carbapenemase activity, e.g. against the carbapenem antibiotics meropenem and imipenem used in treatment of Pseudomonas aeruginosa infection, and contributes to resistance to anti-pseudomonal agents, overview
-
-
?
moxalactam + H2O
(2R)-2-{(R)-carboxy[2-carboxy(4-hydroxyphenyl)acetamido]methoxymethyl}-5-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,6-dihydro-2H-1,3-oxazine-4-carboxylic acid
-
-
-
?
moxalactam + H2O
(2R)-2-{(R)-carboxy[2-carboxy(4-hydroxyphenyl)acetamido]methoxymethyl}-5-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,6-dihydro-2H-1,3-oxazine-4-carboxylic acid
-
-
-
?
nitrocefin + H2O
(2R)-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-5-[(E)-2-(2,4-dinitrophenyl)ethenyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
-
?
nitrocefin + H2O
(2R)-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-5-[(E)-2-(2,4-dinitrophenyl)ethenyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
nitrocefin + H2O
(2R)-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-5-[(E)-2-(2,4-dinitrophenyl)ethenyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
nitrocefin + H2O
(2R)-2-{(R)-carboxy[2-(thiophen-2-yl)acetamido]methyl}-5-[(E)-2-(2,4-dinitrophenyl)ethenyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
-
?
nitrocefin + H2O
(2R)-2-{(R)-carboxy[2-(thiophen-2-yl)acetamido]methyl}-5-[(E)-2-(2,4-dinitrophenyl)ethenyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
nitrocefin + H2O
(2R)-2-{(R)-carboxy[2-(thiophen-2-yl)acetamido]methyl}-5-[(E)-2-(2,4-dinitrophenyl)ethenyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
nitrocefin + H2O
(2R)-2-{(R)-carboxy[2-(thiophen-2-yl)acetamido]methyl}-5-[(E)-2-(2,4-dinitrophenyl)ethenyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
nitrocefin + H2O
(2R)-2-{(R)-carboxy[2-(thiophen-2-yl)acetamido]methyl}-5-[(E)-2-(2,4-dinitrophenyl)ethenyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
?
oxacillin + H2O
(2R,4S)-2-{(R)-carboxy[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]methyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
-
?
oxacillin + H2O
(2R,4S)-2-{(R)-carboxy[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]methyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
penicillin G + H2O
(2R,4S)-2-[(R)-carboxy[(phenylacetyl)amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
-
?
penicillin G + H2O
(2R,4S)-2-[(R)-carboxy[(phenylacetyl)amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
piperacillin + H2O
(2R,4S)-2-[(R)-carboxy[[(2R)-2-[[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino]-2-phenylacetyl]amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
piperacillin + H2O
(2R,4S)-2-[(R)-carboxy[[(2R)-2-[[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino]-2-phenylacetyl]amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
piperacillin + H2O
(2R,4S)-2-[(R)-carboxy[[(2R)-2-[[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino]-2-phenylacetyl]amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
piperacillin + H2O
(2R,4S)-2-[(R)-carboxy[[(2R)-2-[[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino]-2-phenylacetyl]amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
piperacillin + H2O
(2R,4S)-2-[(R)-carboxy[[(2R)-2-[[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino]-2-phenylacetyl]amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
piperacillin + H2O
(2R,4S)-2-[(R)-carboxy[[(2R)-2-[[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino]-2-phenylacetyl]amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
piperacillin + H2O
(2R,4S)-2-[(R)-carboxy[[(2R)-2-[[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino]-2-phenylacetyl]amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
ticarcillin + H2O
(2R,4S)-2-[(R)-carboxy[[(2R)-2-carboxy-2-(thiophen-3-yl)acetyl]amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
ticarcillin + H2O
(2R,4S)-2-[(R)-carboxy[[(2R)-2-carboxy-2-(thiophen-3-yl)acetyl]amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
ticarcillin + H2O
(2R,4S)-2-[(R)-carboxy[[(2R)-2-carboxy-2-(thiophen-3-yl)acetyl]amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
ticarcillin + H2O
(2R,4S)-2-[(R)-carboxy[[(2R)-2-carboxy-2-(thiophen-3-yl)acetyl]amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
ticarcillin + H2O
(2R,4S)-2-[(R)-carboxy[[(2R)-2-carboxy-2-(thiophen-3-yl)acetyl]amino]methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
-
-
-
?
additional information
?
-
-
does not hydrolyse aztreonam
-
-
?
additional information
?
-
-
a VIM-2 enzyme inserted in integron In58, in an isolate from a female cystic fibrosis patient, is resistant to all antimicrobial agents tested except colistin, overview
-
-
?
additional information
?
-
-
antibiotic resistance rates and mechanisms of beta-lactam and aminoglycoside resistance, e.g. against ticarcillin, among human isolates of Pseudomonas aeruginosa isolated in the extra-hospital setting, MIC values of diverse beta-lactam antibiotics, resistance mechanisms, overview
-
-
?
additional information
?
-
-
carbapenem resistance screening of diverse clinical strains by a 2-mercaptopropionic acid inhibition test method, determination of MIC values, overview
-
-
?
additional information
?
-
-
determination of MIC values of SHV-1 for several antibiotics, overview
-
-
?
additional information
?
-
-
genetic variants of beta-lactamases cause resistance to antibiotics cefepime and/or ceftazidime, overview
-
-
?
additional information
?
-
-
occurrence and mechanisms of amikacin resistance and its association with beta-lactamases in Pseudomonas aeruginosa, a Korean nationwide study, gene blaOXA-10 is involved in amikain resistance, overview
-
-
?
additional information
?
-
-
production of beta-lactamases is the main mechanism of resistance to beta-lactams in Gram-negative bacteria, the phenomenon of continuing suppression of bacterial growth after removal of beta-lactamase inhibitors is termed post-beta-lactamase inhibitor effect, PLIE. EDTA combined with carbapenems produces a significant PLIE on VIM-MBL-positive Pseudomonas aeruginosa strains
-
-
?
additional information
?
-
-
screening for beta-lactamase genes in clincal isolates using Etest MBL screening test, The blaVIM-13-producing isolate shows resistance to all beta-lactams, except aztreonam, gentamicin, tobramycin, and ciprofloxacin, VIM-13 confers slightly higher levels of resistance to piperacillin and lower levels of resistance to ceftazidime and cefepime than VIM-1, MIC values, overview
-
-
?
additional information
?
-
screening for beta-lactamase genes in clincal isolates using Etest MBL screening test, The blaVIM-13-producing isolate shows resistance to all beta-lactams, except aztreonam, gentamicin, tobramycin, and ciprofloxacin, VIM-13 confers slightly higher levels of resistance to piperacillin and lower levels of resistance to ceftazidime and cefepime than VIM-1, MIC values, overview
-
-
?
additional information
?
-
screening for beta-lactamase genes in clincal isolates using Etest MBL screening test, The blaVIM-13-producing isolate shows resistance to all beta-lactams, except aztreonam, gentamicin, tobramycin, and ciprofloxacin, VIM-13 confers slightly higher levels of resistance to piperacillin and lower levels of resistance to ceftazidime and cefepime than VIM-1, MIC values, overview
-
-
?
additional information
?
-
-
screening for strains expressing IMP-15 beta-lactamases in clinical human isolates from a Mexican tertiary-care hospital, overview
-
-
?
additional information
?
-
screening for strains expressing IMP-15 beta-lactamases in clinical human isolates from a Mexican tertiary-care hospital, overview
-
-
?
additional information
?
-
screening for strains expressing IMP-15 beta-lactamases in clinical human isolates from a Mexican tertiary-care hospital, overview
-
-
?
additional information
?
-
-
screening for strains expressing VIM-1, and other beta-lactamases in clinical human isolates from a Mexican tertiary-care hospital, overview
-
-
?
additional information
?
-
screening for strains expressing VIM-1, and other beta-lactamases in clinical human isolates from a Mexican tertiary-care hospital, overview
-
-
?
additional information
?
-
screening for strains expressing VIM-1, and other beta-lactamases in clinical human isolates from a Mexican tertiary-care hospital, overview
-
-
?
additional information
?
-
susceptibility and enzymatic activity of metallo-beta-lactamases in Pseudomonas aeruginosa-producing metallo-beta-lactamases, overview
-
-
?
additional information
?
-
-
susceptibility and enzymatic activity of metallo-beta-lactamases in Pseudomonas aeruginosa-producing metallo-beta-lactamases, overview
-
-
?
additional information
?
-
the IMP-9 variant of metallo-beta-lactamases show a broad spectrum antibiotic resistance resulting in an out break in 2005-2007 in China, multidrug-resistant profile of IMP-9 MBL variants, overview
-
-
?
additional information
?
-
-
the IMP-9 variant of metallo-beta-lactamases show a broad spectrum antibiotic resistance resulting in an out break in 2005-2007 in China, multidrug-resistant profile of IMP-9 MBL variants, overview
-
-
?
additional information
?
-
the Pseudomonas aeruginosa strain that contains the mobile metallo-beta-lactamase gene, designated blaVIM-7, located on a plasmid (p07-406), is resistant to all tested antimicrobials except polymyxin B causing an outbreak of infections in Houston, USA, overview
-
-
?
additional information
?
-
-
the Pseudomonas aeruginosa strain that contains the mobile metallo-beta-lactamase gene, designated blaVIM-7, located on a plasmid (p07-406), is resistant to all tested antimicrobials except polymyxin B causing an outbreak of infections in Houston, USA, overview
-
-
?
additional information
?
-
-
screening for MBL and ESBL variants using different test methods, overview
-
-
?
additional information
?
-
VIM-2 has a broad substrate hydrolysis range, which includes penicillins, cephalosporins, cephamycins, oxacephamycins and carbapenems but not monobactams. Amongst the carbapenems, VIM-2 better hydrolyses meropenem than imipenem
-
-
?
additional information
?
-
-
VIM-2 has a broad substrate hydrolysis range, which includes penicillins, cephalosporins, cephamycins, oxacephamycins and carbapenems but not monobactams. Amongst the carbapenems, VIM-2 better hydrolyses meropenem than imipenem
-
-
?
additional information
?
-
a single amino acid difference at position 170 of the GES-1, GES-2, and GES-5 enzymes is responsible for the expansion of their substrate profile to include carbapenem antibiotics. The catalytic efficiency of the enzymes with carbapenems meropenem, ertapenem, and doripenem progressively increases 100fold from GES-1 to -5, mainly due to an increase in the rate of acylation. While acylation is rate limiting for GES-1 and GES-2 for all three carbapenems, acylation and deacylation are indistinguishable for GES-5. Only the core structure of the antibiotic interacts with the active site of the GES-2 beta-lactamase. The identical core structures of ertapenem, doripenem, and meropenem are likely responsible for the observed similarities in the kinetics with these carbapenems. The lack of a methyl group in the core structure of imipenem may provide a structural rationale for the increase in turnover of this carbapenem by the GES beta-lactamases
-
-
?
additional information
?
-
a single amino acid difference at position 170 of the GES-1, GES-2, and GES-5 enzymes is responsible for the expansion of their substrate profile to include carbapenem antibiotics. The catalytic efficiency of the enzymes with carbapenems meropenem, ertapenem, and doripenem progressively increases 100fold from GES-1 to -5, mainly due to an increase in the rate of acylation. While acylation is rate limiting for GES-1 and GES-2 for all three carbapenems, acylation and deacylation are indistinguishable for GES-5. Only the core structure of the antibiotic interacts with the active site of the GES-2 beta-lactamase. The identical core structures of ertapenem, doripenem, and meropenem are likely responsible for the observed similarities in the kinetics with these carbapenems. The lack of a methyl group in the core structure of imipenem may provide a structural rationale for the increase in turnover of this carbapenem by the GES beta-lactamases
-
-
?
additional information
?
-
a single amino acid difference at position 170 of the GES-1, GES-2, and GES-5 enzymes is responsible for the expansion of their substrate profile to include carbapenem antibiotics. The catalytic efficiency of the enzymes with carbapenems meropenem, ertapenem, and doripenem progressively increases 100fold from GES-1 to -5, mainly due to an increase in the rate of acylation. While acylation is rate limiting for GES-1 and GES-2 for all three carbapenems, acylation and deacylation are indistinguishable for GES-5. Only the core structure of the antibiotic interacts with the active site of the GES-2 beta-lactamase. The identical core structures of ertapenem, doripenem, and meropenem are likely responsible for the observed similarities in the kinetics with these carbapenems. The lack of a methyl group in the core structure of imipenem may provide a structural rationale for the increase in turnover of this carbapenem by the GES beta-lactamases
-
-
?
additional information
?
-
a single amino acid difference at position 170 of the GES-1, GES-2, and GES-5 enzymes is responsible for the expansion of their substrate profile to include carbapenem antibiotics. The catalytic efficiency of the enzymes with carbapenems meropenem, ertapenem, and doripenem progressively increases 100fold from GES-1 to -5, mainly due to an increase in the rate of acylation. While acylation is rate limiting for GES-1 and GES-2 for all three carbapenems, acylation and deacylation are indistinguishable for GES-5. The identical core structures of ertapenem, doripenem, and meropenem are likely responsible for the observed similarities in the kinetics with these carbapenems. The lack of a methyl group in the core structure of imipenem may provide a structural rationale for the increase in turnover of this carbapenem by the GES beta-lactamases
-
-
?
additional information
?
-
a single amino acid difference at position 170 of the GES-1, GES-2, and GES-5 enzymes is responsible for the expansion of their substrate profile to include carbapenem antibiotics. The catalytic efficiency of the enzymes with carbapenems meropenem, ertapenem, and doripenem progressively increases 100fold from GES-1 to -5, mainly due to an increase in the rate of acylation. While acylation is rate limiting for GES-1 and GES-2 for all three carbapenems, acylation and deacylation are indistinguishable for GES-5. The identical core structures of ertapenem, doripenem, and meropenem are likely responsible for the observed similarities in the kinetics with these carbapenems. The lack of a methyl group in the core structure of imipenem may provide a structural rationale for the increase in turnover of this carbapenem by the GES beta-lactamases
-
-
?
additional information
?
-
a single amino acid difference at position 170 of the GES-1, GES-2, and GES-5 enzymes is responsible for the expansion of their substrate profile to include carbapenem antibiotics. The catalytic efficiency of the enzymes with carbapenems meropenem, ertapenem, and doripenem progressively increases 100fold from GES-1 to -5, mainly due to an increase in the rate of acylation. While acylation is rate limiting for GES-1 and GES-2 for all three carbapenems, acylation and deacylation are indistinguishable for GES-5. The identical core structures of ertapenem, doripenem, and meropenem are likely responsible for the observed similarities in the kinetics with these carbapenems. The lack of a methyl group in the core structure of imipenem may provide a structural rationale for the increase in turnover of this carbapenem by the GES beta-lactamases
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
a beta-lactam + H2O
a substituted beta-amino acid
-
-
-
-
?
biapenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-[(6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium-6-yl)sulfanyl]-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylate
-
activity in resistant strains
-
-
?
carbapenem + H2O
[(2R)-2,3-dihydro-1H-pyrrol-2-yl]acetic acid
-
-
-
?
cefazolin + H2O
(2R)-2-[(R)-carboxy[(1H-tetrazol-1-ylacetyl)amino]methyl]-5-[[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
-
?
cefoperazone + H2O
(2R)-2-[(R)-carboxy{[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}methyl]-5-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
-
?
cephalexin + H2O
(2R)-2-[(R)-[[(2R)-2-amino-2-phenylacetyl]amino](carboxy)methyl]-5-methyl-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
-
?
cephaloridine + H2O
(2R)-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-5-(pyridinium-1-ylmethyl)-3,6-dihydro-2H-1,3-thiazine-4-carboxylate
-
-
-
-
?
cephalothin + H2O
(2R)-5-[(acetyloxy)methyl]-2-[(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
-
-
-
-
?
doripenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4-methyl-3-([(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
ertapenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-([(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl)-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-[[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl]-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
additional information
?
-
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
-
-
?
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
activity in resistant strains
-
-
?
imipenem + H2O
(5R)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-4,5-dihydro-1H-pyrrole-2-carboxylic acid
the enzyme shows carbapenemase activity, e.g. against the carbapenem antibiotics meropenem and imipenem used in treatment of Pseudomonas aeruginosa infection, and contributes to resistance to anti-pseudomonal agents, overview
-
-
?
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
-
activity in resistant strains
-
-
?
meropenem + H2O
(4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
the enzyme shows carbapenemase activity, e.g. against the carbapenem antibiotics meropenem and imipenem used in treatment of Pseudomonas aeruginosa infection, and contributes to resistance to anti-pseudomonal agents, overview
-
-
?
additional information
?
-
-
a VIM-2 enzyme inserted in integron In58, in an isolate from a female cystic fibrosis patient, is resistant to all antimicrobial agents tested except colistin, overview
-
-
?
additional information
?
-
-
antibiotic resistance rates and mechanisms of beta-lactam and aminoglycoside resistance, e.g. against ticarcillin, among human isolates of Pseudomonas aeruginosa isolated in the extra-hospital setting, MIC values of diverse beta-lactam antibiotics, resistance mechanisms, overview
-
-
?
additional information
?
-
-
carbapenem resistance screening of diverse clinical strains by a 2-mercaptopropionic acid inhibition test method, determination of MIC values, overview
-
-
?
additional information
?
-
-
determination of MIC values of SHV-1 for several antibiotics, overview
-
-
?
additional information
?
-
-
genetic variants of beta-lactamases cause resistance to antibiotics cefepime and/or ceftazidime, overview
-
-
?
additional information
?
-
-
occurrence and mechanisms of amikacin resistance and its association with beta-lactamases in Pseudomonas aeruginosa, a Korean nationwide study, gene blaOXA-10 is involved in amikain resistance, overview
-
-
?
additional information
?
-
-
production of beta-lactamases is the main mechanism of resistance to beta-lactams in Gram-negative bacteria, the phenomenon of continuing suppression of bacterial growth after removal of beta-lactamase inhibitors is termed post-beta-lactamase inhibitor effect, PLIE. EDTA combined with carbapenems produces a significant PLIE on VIM-MBL-positive Pseudomonas aeruginosa strains
-
-
?
additional information
?
-
-
screening for beta-lactamase genes in clincal isolates using Etest MBL screening test, The blaVIM-13-producing isolate shows resistance to all beta-lactams, except aztreonam, gentamicin, tobramycin, and ciprofloxacin, VIM-13 confers slightly higher levels of resistance to piperacillin and lower levels of resistance to ceftazidime and cefepime than VIM-1, MIC values, overview
-
-
?
additional information
?
-
screening for beta-lactamase genes in clincal isolates using Etest MBL screening test, The blaVIM-13-producing isolate shows resistance to all beta-lactams, except aztreonam, gentamicin, tobramycin, and ciprofloxacin, VIM-13 confers slightly higher levels of resistance to piperacillin and lower levels of resistance to ceftazidime and cefepime than VIM-1, MIC values, overview
-
-
?
additional information
?
-
screening for beta-lactamase genes in clincal isolates using Etest MBL screening test, The blaVIM-13-producing isolate shows resistance to all beta-lactams, except aztreonam, gentamicin, tobramycin, and ciprofloxacin, VIM-13 confers slightly higher levels of resistance to piperacillin and lower levels of resistance to ceftazidime and cefepime than VIM-1, MIC values, overview
-
-
?
additional information
?
-
-
screening for strains expressing IMP-15 beta-lactamases in clinical human isolates from a Mexican tertiary-care hospital, overview
-
-
?
additional information
?
-
screening for strains expressing IMP-15 beta-lactamases in clinical human isolates from a Mexican tertiary-care hospital, overview
-
-
?
additional information
?
-
screening for strains expressing IMP-15 beta-lactamases in clinical human isolates from a Mexican tertiary-care hospital, overview
-
-
?
additional information
?
-
-
screening for strains expressing VIM-1, and other beta-lactamases in clinical human isolates from a Mexican tertiary-care hospital, overview
-
-
?
additional information
?
-
screening for strains expressing VIM-1, and other beta-lactamases in clinical human isolates from a Mexican tertiary-care hospital, overview
-
-
?
additional information
?
-
screening for strains expressing VIM-1, and other beta-lactamases in clinical human isolates from a Mexican tertiary-care hospital, overview
-
-
?
additional information
?
-
susceptibility and enzymatic activity of metallo-beta-lactamases in Pseudomonas aeruginosa-producing metallo-beta-lactamases, overview
-
-
?
additional information
?
-
-
susceptibility and enzymatic activity of metallo-beta-lactamases in Pseudomonas aeruginosa-producing metallo-beta-lactamases, overview
-
-
?
additional information
?
-
the IMP-9 variant of metallo-beta-lactamases show a broad spectrum antibiotic resistance resulting in an out break in 2005-2007 in China, multidrug-resistant profile of IMP-9 MBL variants, overview
-
-
?
additional information
?
-
-
the IMP-9 variant of metallo-beta-lactamases show a broad spectrum antibiotic resistance resulting in an out break in 2005-2007 in China, multidrug-resistant profile of IMP-9 MBL variants, overview
-
-
?
additional information
?
-
the Pseudomonas aeruginosa strain that contains the mobile metallo-beta-lactamase gene, designated blaVIM-7, located on a plasmid (p07-406), is resistant to all tested antimicrobials except polymyxin B causing an outbreak of infections in Houston, USA, overview
-
-
?
additional information
?
-
-
the Pseudomonas aeruginosa strain that contains the mobile metallo-beta-lactamase gene, designated blaVIM-7, located on a plasmid (p07-406), is resistant to all tested antimicrobials except polymyxin B causing an outbreak of infections in Houston, USA, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Murata, T.; Minami, S.; Yasuda, K.; Iyobe, S.; Inoue, M.; Mitsuhashi, S.
Purification and properties of cephalosporinase from Pseudomonas aeruginosa
J. Antibiot.
9
1164-1170
1981
Pseudomonas aeruginosa, Pseudomonas aeruginosa Dalgleish, Pseudomonas aeruginosa GN10362
brenda
Matthew, M.
Properies of the beta-lactamase specified by the Pseudomonas plasmid R151
FEMS Microbiol. Lett.
4
241-244
1978
Pseudomonas aeruginosa, Pseudomonas aeruginosa Dalgleish, Pseudomonas aeruginosa PU21 R151
-
brenda
Matthew, M.; Sykes, R.B.
Properties of the beta-lactamase specified by the Pseudomonas plasmid RPL11
J. Bacteriol.
132
341-345
1977
Pseudomonas aeruginosa, Pseudomonas aeruginosa Dalgleish, Pseudomonas aeruginosa PU21 RPL11
brenda
Furth, A.J.
Purification and properties of a constitutive beta-lactamase from Pseudomonas aeruginosa strain Dalgleish
Biochim. Biophys. Acta
377
431-443
1975
Pseudomonas aeruginosa, Pseudomonas aeruginosa Dalgleish
brenda
Hammond, G.G.; Huber, J.L.; Greenlee, M.L.; Laub, J.B.; Young, K.; Silver, L.L.; Balkovec, J.M.; Pryor, K.A.D.; Wu, J-K.; Leiting, B.; Pompliano, D.L.; Toney,J.H.
Inhibition of IMP-1 metallo-beta-lactamase and sensitisation of IMP-1-producing bacteria by thioester derivates
FEMS Microbiol. Lett.
179
2193-2199
1999
Bacteroides fragilis, Pseudomonas aeruginosa, Pseudomonas aeruginosa Dalgleish, Pseudomonas aeruginosa Cl5673
-
brenda
Lim, D.; Sanschagrin, F.; Passmore, L.; De Castro, L.; Levesque, R.C.; Strynadka, N.C.
Insights into the molecular basis for the carbenicillinase activity of PSE-4 beta-lactamase from crystallographic and kinetic studies
Biochemistry
40
395-402
2001
Pseudomonas aeruginosa (P16897), Pseudomonas aeruginosa
brenda
Paetzel, M.; Danel, F.; de Castro, L.; Mosimann, S.C.; Page, M.G.; Strynadka, N.C.
Crystal structure of the class D beta-lactamase OXA-10
Nat. Struct. Biol.
7
918-925
2000
Pseudomonas aeruginosa (P14489), Pseudomonas aeruginosa
brenda
Girlich, D.; Naas, T.; Nordmann, P.
Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa
Antimicrob. Agents Chemother.
48
2043-2048
2004
Pseudomonas aeruginosa (Q6PL88), Pseudomonas aeruginosa
brenda
Castanheira, M.; Toleman, M.A.; Jones, R.N.; Schmidt, F.J.; Walsh, T.R.
Molecular characterization of a beta-lactamase gene, blaGIM-1, encoding a new subclass of metallo-beta-lactamase
Antimicrob. Agents Chemother.
48
4654-4661
2004
Pseudomonas aeruginosa (Q704U4), Pseudomonas aeruginosa
brenda
Poirel, L.; Brinas, L.; Verlinde, A.; Ide, L.; Nordmann, P.
BEL-1, a novel clavulanic acid-inhibited extended-spectrum beta-lactamase, and the class 1 integron In120 in Pseudomonas aeruginosa
Antimicrob. Agents Chemother.
49
3743-3748
2005
Pseudomonas aeruginosa (Q3SAW3), Pseudomonas aeruginosa
brenda
Quinteira, S.; Sousa, J.C.; Peixe, L.
Characterization of In100, a new integron carrying a metallo-{beta}-lactamase and a carbenicillinase, from Pseudomonas aeruginosa
Antimicrob. Agents Chemother.
49
451-453
2005
Pseudomonas aeruginosa (Q9K2N0), Pseudomonas aeruginosa
brenda
Jin, W.; Arakawa, Y.; Yasuzawa, H.; Taki, T.; Hashiguchi, R.; Mitsutani, K.; Shoga, A.; Yamaguchi, Y.; Kurosaki, H.; Shibata, N.; Ohta, M.; Goto, M.
Comparative study of the inhibition of metallo-beta-lactamases (IMP-1 and VIM-2) by thiol compounds that contain a hydrophobic group
Biol. Pharm. Bull.
27
851-856
2004
Pseudomonas aeruginosa, Serratia marcescens
brenda
Luzzaro, F.; Endimiani, A.; Docquier, J.D.; Mugnaioli, C.; Bonsignori, M.; Amicosante, G.; Rossolini, G.M.; Toniolo, A.
Prevalence and characterization of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa
Diagn. Microbiol. Infect. Dis.
48
131-135
2004
Pseudomonas aeruginosa
brenda
Kong, K.F.; Jayawardena, S.R.; Del Puerto, A.; Wiehlmann, L.; Laabs, U.; Tuemmler, B.; Mathee, K.
Characterization of poxB, a chromosomal-encoded Pseudomonas aeruginosa oxacillinase
Gene
358
82-92
2005
Pseudomonas aeruginosa
brenda
Marchiaro, P.; Tomatis, P.E.; Mussi, M.A.; Pasteran, F.; Viale, A.M; Limansky, A.S.; Vila, A.J.
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain
Antimicrob. Agents Chemother.
52
2250-2252
2007
Pseudomonas aeruginosa, Pseudomonas aeruginosa M5109
brenda
Yan, J.J.; Hsueh, P.R.; Lu, J.J.; Chan, F.Y.; Ko, W.C.; Wu, J.J.
Characterization of acquired beta-lactamases and their genetic support in multidrug-resistant Pseudomonas aeruginosa isolates in Taiwan: the prevalence of unusual integrons
J. Antimicrob. Chemother.
58
530-536
2006
Pseudomonas aeruginosa, Pseudomonas aeruginosa (Q27JM4), Pseudomonas aeruginosa (Q6QJ55), Pseudomonas aeruginosa (Q7BHJ5), Pseudomonas aeruginosa (Q9F629)
brenda
Yamaguchi, Y.; Jin, W.; Matsunaga, K.; Ikemizu, S.; Yamagata, Y.; Wachino, J.; Shibata, N.; Arakawa, Y.; Kurosaki, H.
Crystallographic investigation of the inhibition mode of a VIM-2 metallo-beta-lactamase from Pseudomonas aeruginosa by a mercaptocarboxylate inhibitor
J. Med. Chem.
50
6647-6653
2007
Pseudomonas aeruginosa
brenda
Garza-Ramos, U.; Morfin-Otero, R.; Sader, H.S.; Jones, R.N.; Hernández, E.; Rodriguez-Noriega, E.; Sanchez, A.; Carrillo, B.; Esparza-Ahumada, S.; Silva-Sanchez, J.
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico
Antimicrob. Agents Chemother.
52
2943-2946
2008
Pseudomonas aeruginosa, Pseudomonas aeruginosa (Q53CM3), Pseudomonas aeruginosa (Q7AYX1)
brenda
Li, H.; Toleman, M.A.; Bennett, P.M.; Jones, R.N.; Walsh, T.R.
Complete Sequence of p07-406, a 24,179-base-pair plasmid harboring the blaVIM-7 metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States
Antimicrob. Agents Chemother.
52
3099-3105
2008
Pseudomonas aeruginosa (Q840P9), Pseudomonas aeruginosa
brenda
Juan, C.; Beceiro, A.; Gutiérrez, O.; Albertí, S.; Garau, M.; Pérez, J.L.; Bou, G.; Oliver, A.
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain
Antimicrob. Agents Chemother.
52
3589-3596
2008
Pseudomonas aeruginosa, Pseudomonas aeruginosa (Q2HY42), Pseudomonas aeruginosa (Q9XAY4), Pseudomonas aeruginosa SL2 (Q2HY42), Pseudomonas aeruginosa SL2 (Q9XAY4)
brenda
Takeda, S.; Nakai, T.; Ikeda, F.; Hatano, K.
Overproduction of a metallo-beta-lactamase by a strong promoter causes high-level imipenem resistance in a clinical isolate of Pseudomonas aeruginosa
Chemotherapy
54
181-187
2008
Pseudomonas aeruginosa (Q7DH52), Pseudomonas aeruginosa
brenda
Bedenic, B.; Vranes, J.; Sviben, M.; Beader, N.; Kalenic, S.
Postantibiotic and post-beta-lactamase inhibitor effect of carbapenems combined with EDTA against Pseudomonas aeruginosa strains producing VIM-metallo beta-lactamases
Chemotherapy
54
188-193
2008
Pseudomonas aeruginosa
brenda
Edalucci, E.; Spinelli, R.; Dolzani, L.; Riccio, M.L.; Dubois, V.; Tonin, E.A.; Rossolini, G.M.; Lagatolla, C.
Acquisition of different carbapenem resistance mechanisms by an epidemic clonal lineage of Pseudomonas aeruginosa
Clin. Microbiol. Infect.
14
88-90
2008
Pseudomonas aeruginosa, Pseudomonas aeruginosa (Q7BHJ5)
brenda
Motoshima, M.; Yanagihara, K.; Yamamoto, K.; Morinaga, Y.; Matsuda, J.; Sugahara, K.; Hirakata, Y.; Yamada, Y.; Kohno, S.; Kamihira, S.
Quantitative detection of metallo-beta-lactamase of blaIMP-cluster-producing Pseudomonas aeruginosa by real-time polymerase chain reaction with melting curve analysis for rapid diagnosis and treatment of nosocomial infection
Diagn. Microbiol. Infect. Dis.
61
222-226
2008
Pseudomonas aeruginosa (Q79MP6), Pseudomonas aeruginosa, Pseudomonas aeruginosa blaIMP-cluster-producing (Q79MP6)
brenda
Falagas, M.E.; Kanellopoulou, M.D.; Karageorgopoulos, D.E.; Dimopoulos, G.; Rafailidis, P.I.; Skarmoutsou, N.D.; Papafrangas, E.A.
Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin
Eur. J. Clin. Microbiol. Infect. Dis.
27
439-443
2008
Pseudomonas aeruginosa
brenda
Pena, A.; Donato, A.M.; Alves, A.F.; Leitão, R.; Cardoso, O.M.
Detection of Pseudomonas aeruginosa producing metallo-beta-lactamase VIM-2 in a central hospital from Portugal
Eur. J. Clin. Microbiol. Infect. Dis.
27
1269-1271
2008
Pseudomonas aeruginosa
brenda
Cardoso, O.; Alves, A.F.; Leitao, R.
Metallo-beta-lactamase VIM-2 in Pseudomonas aeruginosa isolates from a cystic fibrosis patient
Int. J. Antimicrob. Agents
31
375-379
2008
Pseudomonas aeruginosa
brenda
Chao, Z.; Xiao-Feng, W.; Dan-Hong, S.; Jin-Ping, Y.; Nan-Shan, Z.
Outbreak of Pseudomonas aeruginosa producing IMP-9-type metallo-beta-lactamase in Guangzhou, China
Int. J. Antimicrob. Agents
32
363-365
2008
Pseudomonas aeruginosa (P14489), Pseudomonas aeruginosa
brenda
Miyajima, Y.; Hiramatsu, K.; Mizukami, E.; Morinaga, R.; Ishii, H.; Shirai, R.; Kishi, K.; Tokimatsu, I.; Saikawa, T.; Kadota, J.
In vitro and in vivo potency of polymyxin B against IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa
Int. J. Antimicrob. Agents
32
437-440
2008
Pseudomonas aeruginosa
brenda
Yakupogullari, Y.; Poirel, L.; Bernabeu, S.; Kizirgil, A.; Nordmann, P.
Multidrug-resistant Pseudomonas aeruginosa isolate co-expressing extended-spectrum beta-lactamase PER-1 and metallo-beta-lactamase VIM-2 from Turkey
J. Antimicrob. Chemother.
61
221-222
2008
Pseudomonas aeruginosa
brenda
Samuelsen, O.; Buarø, L.; Giske, C.G.; Simonsen, G.S.; Aasnaes, B.; Sundsfjord, A.
Evaluation of phenotypic tests for the detection of metallo-beta-lactamase-producing Pseudomonas aeruginosa in a low prevalence country
J. Antimicrob. Chemother.
61
827-830
2008
Pseudomonas aeruginosa
brenda
Dubois, V.; Arpin, C.; Dupart, V.; Scavelli, A.; Coulange, L.; André, C.; Fischer, I.; Grobost, F.; Brochet, J.P.; Lagrange, I.; Dutilh, B.; Jullin, J.; Noury, P.; Larribet, G.; Quentin, C.
Beta-lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres)
J. Antimicrob. Chemother.
62
316-323
2008
Pseudomonas aeruginosa
brenda
Kim, J.Y.; Park, Y.J.; Kwon, H.J.; Han, K.; Kang, M.W.; Woo, G.J.
Occurrence and mechanisms of amikacin resistance and its association with beta-lactamases in Pseudomonas aeruginosa: a Korean nationwide study
J. Antimicrob. Chemother.
62
479-483
2008
Pseudomonas aeruginosa
brenda
Picao, R.C.; Andrade, S.S.; Nicoletti, A.G.; Campana, E.H.; Moraes, G.C.; Mendes, R.E.; Gales, A.C.
Metallo-beta-Lactamase detection: comparative evaluation of double-disk synergy versus combined disk tests for IMP, GIM, SIM, SPM or VIM-producing isolates
J. Clin. Microbiol.
46
2028-2037
2008
Acinetobacter sp., Enterobacter cloacae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Pseudomonas putida, Serratia marcescens
brenda
Cheng, X.; Wang, P.; Wang, Y.; Zhang, H.; Tao, C.; Yang, W.; Liu, M.; Jia, W.
Identification and distribution of the clinical isolates of imipenem-resistant Pseudomonas aeruginosa carrying metallo-beta-lactamase and/or class 1 integron genes
J. Huazhong Univ. Sci. Technol. Med. Sci.
28
235-238
2008
Pseudomonas aeruginosa
brenda
Tsuchimochi, N.; Takuma, T.; Shimono, N.; Nagasaki, Y.; Uchida, Y.; Harada, M.
Antimicrobial susceptibility and molecular epidemiological analysis of clinical strains of Pseudomonas aeruginosa
J. Infect. Chemother.
14
99-104
2008
Pseudomonas aeruginosa
brenda
Garcia-Saez, I.; Docquier, J.D.; Rossolini, G.M.; Dideberg, O.
The three-dimensional structure of VIM-2, a Zn-beta-lactamase from Pseudomonas aeruginosa in its reduced and oxidised form
J. Mol. Biol.
375
604-611
2008
Pseudomonas aeruginosa (Q9K2N0), Pseudomonas aeruginosa
brenda
David, M.; Lemeland, J.F.; Boyer, S.
Emergence of extended-spectrum beta-lactamases in Pseudomonas aeruginosa: about 24 cases at Rouen university hospital
Pathol. Biol.
56
429-434
2008
Pseudomonas aeruginosa
brenda
Kalai Blagui, S.; Achour, W.; Abdeladhim, A.; Ben Hassen, A.
Identification of SHV-type extended spectrum beta-lactamase genes in Pseudomonas aeruginosa by PCR-restriction fragment length polymorphism and insertion site restriction-PCR.
Pathol. Biol.
57
420-424
2008
Pseudomonas aeruginosa
brenda
Sevillano, E.; Gallego, L.; García-Lobo, J.M.
First detection of the OXA-40 carbapenemase in P. aeruginosa isolates, located on a plasmid also found in A. baumannii
Pathol. Biol.
57
493-495
2008
Pseudomonas aeruginosa
brenda
Kalai Blagui, S.; Achour, W.; Bejaoui, M.; Abdeladhim, A.; Ben Hassen, A.
Detection of SHV-1 beta-lactamase in Pseudomonas aeruginosa strains by genetic methods
Pathol. Biol.
57
e73-e75
2008
Pseudomonas aeruginosa
brenda
Samuelsen, O.; Castanheira, M.; Walsh, T.R.; Spencer, J.
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta -lactamase family
Antimicrob. Agents Chemother.
52
2905-2908
2008
Pseudomonas aeruginosa (Q840P9)
brenda
Drawz, S.M.; Bethel, C.R.; Doppalapudi, V.R.; Sheri, A.; Pagadala, S.R.; Hujer, A.M.; Skalweit, M.J.; Anderson, V.E.; Chen, S.G.; Buynak, J.D.; Bonomo, R.A.
Penicillin sulfone inhibitors of class D beta-lactamases
Antimicrob. Agents Chemother.
54
1414-1424
2010
Acinetobacter sp., Pseudomonas aeruginosa, plasmid RGN238
brenda
Hiraiwa, Y.; Morinaka, A.; Fukushima, T.; Kudo, T.
Metallo-beta-lactamase inhibitory activity of phthalic acid derivatives
Bioorg. Med. Chem. Lett.
19
5162-5165
2009
Pseudomonas aeruginosa
brenda
Lassaux, P.; Traore, D.A.; Loisel, E.; Favier, A.; Docquier, J.D.; Sohier, J.S.; Laurent, C.; Bebrone, C.; Frere, J.M.; Ferrer, J.L.; Galleni, M.
Biochemical and structural characterization of the subclass B1 metallo-beta-lactamase VIM-4
Antimicrob. Agents Chemother.
55
1248-1255
2011
Pseudomonas aeruginosa (Q8KRJ3), Pseudomonas aeruginosa
brenda
Borgianni, L.; Prandi, S.; Salden, L.; Santella, G.; Hanson, N.D.; Rossolini, G.M.; Docquier, J.D.
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States
Antimicrob. Agents Chemother.
55
140-145
2011
Pseudomonas aeruginosa (Q5U807), Pseudomonas aeruginosa, Pseudomonas aeruginosa PS297 (Q5U807)
brenda
Santella, G.; Docquier, J.D.; Gutkind, G.; Rossolini, G.M.; Radice, M.
Purification and biochemical characterization of IMP-13 metallo-beta-lactamase
Antimicrob. Agents Chemother.
55
399-401
2011
Pseudomonas aeruginosa (Q7WYA8)
brenda
Tan, Q.; Ogawa, A.M.; Painter, R.E.; Park, Y.W.; Young, K.; DiNinno, F.P.
4,7-Dichloro benzothien-2-yl sulfonylaminomethyl boronic acid: first boronic acid-derived beta-lactamase inhibitor with class A, C, and D activity
Bioorg. Med. Chem. Lett.
20
2622-2624
2010
Klebsiella pneumoniae (P0A3M1), Pseudomonas aeruginosa (Q6LBN9), Acinetobacter baumannii (Q8RLA6), Acinetobacter baumannii
brenda
Borra, P.S.; Leiros, H.K.; Ahmad, R.; Spencer, J.; Leiros, I.; Walsh, T.R.; Sundsfjord, A.; Samuelsen, O.
Structural and computational investigations of VIM-7: insights into the substrate specificity of vim metallo-beta-lactamases
J. Mol. Biol.
411
174-189
2011
Pseudomonas aeruginosa (Q840P9), Pseudomonas aeruginosa
brenda
Aitha, M.; Marts, A.R.; Bergstrom, A.; Moeller, A.J.; Moritz, L.; Turner, L.; Nix, J.C.; Bonomo, R.A.; Page, R.C.; Tierney, D.L.; Crowder, M.W.
Biochemical, mechanistic, and spectroscopic characterization of metallo-beta-lactamase VIM-2
Biochemistry
53
7321-7331
2014
Pseudomonas aeruginosa (Q9K2N0)
brenda
Stewart, N.K.; Smith, C.A.; Frase, H.; Black, D.J.; Vakulenko, S.B.
Kinetic and structural requirements for carbapenemase activity in GES-type beta-lactamases
Biochemistry
54
588-597
2015
Pseudomonas aeruginosa (A0EL75), Pseudomonas aeruginosa (Q7BEB3), Pseudomonas aeruginosa (Q93F76)
brenda